BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57:2135-2142. [PMID: 23322699 DOI: 10.1002/hep.26266] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Liu C. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: Resolved and unresolved issues: Treatment of dual hepatitis C and B. J Gastroenterol Hepatol 2014;29:26-30. [DOI: 10.1111/jgh.12421] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
2 Huang Y, Li MH, Hou M, Xie Y. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals. Hepatobiliary Pancreat Dis Int 2017;16:470-9. [PMID: 28992878 DOI: 10.1016/S1499-3872(17)60044-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Shiffman ML, Gunn NT. Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Curr Hepatology Rep 2017;16:169-77. [DOI: 10.1007/s11901-017-0352-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Yen YH, Kee KM, Kuo FY, Chang KC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort. Medicine (Baltimore) 2018;97:e13383. [PMID: 30557991 DOI: 10.1097/MD.0000000000013383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
6 Guo X, Yang G, Yuan J, Ruan P, Zhang M, Chen X, Zhou B. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. PLoS One. 2013;8:e77911. [PMID: 24147097 DOI: 10.1371/journal.pone.0077911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
7 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
8 Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int 2015;35:35-43. [DOI: 10.1111/liv.12712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
10 Yen YH, Huang CM, Wei KL, Wang JH, Lu SN, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Sci Rep 2016;6:33816. [PMID: 27665934 DOI: 10.1038/srep33816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Liu TW, Yeh ML, Huang CF, Lin IL, Huang JF, Dai CY, Chen YL, Chuang WL, Yu ML. Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. Kaohsiung J Med Sci. 2015;31:26-33. [PMID: 25600917 DOI: 10.1016/j.kjms.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI, Huang JF, Lu SN, Dai CY, Jen CL, Yuan Y, L'Italien G, Wang LY, Lee MH, Yu ML, Chuang WL, Chen CJ. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget 2017;8:43925-33. [PMID: 28159934 DOI: 10.18632/oncotarget.14937] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
13 Tillmann HL. Hepatitis C virus infection: when is a cure not a cure? J Infect Dis 2014;209:6-8. [PMID: 24127562 DOI: 10.1093/infdis/jit543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, Yang JF, Lin ZY, Chen SC, Wang LY, Dai CY, Huang JF, Chuang WL, Yu ML. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol. 2014;61:67-74. [PMID: 24613362 DOI: 10.1016/j.jhep.2014.02.022] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 10.8] [Reference Citation Analysis]
15 Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20(11): 2955-2961 [PMID: 24659886 DOI: 10.3748/wjg.v20.i11.2955] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
16 Suda T, Shimakami T, Shirasaki T, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents. Journal of Hepatology 2017;67:1108-11. [DOI: 10.1016/j.jhep.2017.07.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
17 Pawlowska M, Domagalski K. Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12317] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Sato K, Kobayashi T, Yamazaki Y, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C: HBV reactivation during DAA-based therapy. Hepatol Res 2017;47:1346-53. [DOI: 10.1111/hepr.12905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
19 Méndez-sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-ferraz ML, Soza A, Mendes-correa MC, Chávez-tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-avila JF, Contreras F, Moraes-coelho HS, Parise ER, Bessone F, Uribe M. Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology 2014;13:S4-S66. [DOI: 10.1016/s1665-2681(19)30920-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Liu CJ, Chen PJ, Chen DS, Tseng TC, Kao JH. Perspectives on dual hepatitis B and C infection in Taiwan. J Formos Med Assoc 2016;115:298-305. [PMID: 26188762 DOI: 10.1016/j.jfma.2015.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
21 Coppola N, Marrone A, Pisaturo M, Starace M, Signoriello G, Gentile I, Adinolfi LE, Sagnelli E, Zampino R. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis. 2014;33:559-567. [PMID: 24081499 DOI: 10.1007/s10096-013-1985-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
22 Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol 2014; 20(40): 14559-14567 [PMID: 25356020 DOI: 10.3748/wjg.v20.i40.14559] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
23 Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol 2018;6:296-305. [PMID: 30271742 DOI: 10.14218/JCTH.2018.00016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
24 Liu CJ, Sheen IS, Chen CY, Chuang WL, Wang HY, Tseng KC, Chang TT, Yang J, Massetto B, Suri V, Camus G, Jiang D, Zhang F, Gaggar A, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment. Clin Infect Dis 2021:ciab971. [PMID: 34864948 DOI: 10.1093/cid/ciab971] [Reference Citation Analysis]
25 Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine 2014;9:2051-67. [PMID: 24812506 DOI: 10.2147/IJN.S41822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
26 Liu CJ, Chen PJ. Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. Liver Int 2021. [PMID: 34402183 DOI: 10.1111/liv.15040] [Reference Citation Analysis]
27 Pisaturo M, Macera M, Alessio L, Calò F, Coppola N. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses 2019;11:E850. [PMID: 31540223 DOI: 10.3390/v11090850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
28 Wahid B, Saleem K, Waqar M, Wasim M, Idrees M. Successful treatment of HCV/TB co-infected patient with sofosbuvir and daclatasvir: a case report. Future Virology 2018;13:317-21. [DOI: 10.2217/fvl-2017-0141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Yeh ML, Hsieh MY, Huang CI, Huang CF, Hsieh MH, Liang PC, Lin YH, Hou NJ, Lin ZY, Chen SC. Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. Medicine (Baltimore). 2015;94:e1837. [PMID: 26496327 DOI: 10.1097/md.0000000000001837] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
31 Chang JJ, Mohtashemi N, Bhattacharya D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV/AIDS Rep 2018;15:172-81. [PMID: 29572624 DOI: 10.1007/s11904-018-0379-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
32 Yeh ML, Hung CH, Tseng KC, Lai HC, Chen CY, Kuo HT, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang CF, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Liu CJ, Yu ML. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Hepatol Int 2021. [PMID: 34365587 DOI: 10.1007/s12072-021-10220-8] [Reference Citation Analysis]
33 Lai CL, Yuen MF. Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med. 2015;5:pii a021527. [PMID: 26033083 DOI: 10.1101/cshperspect.a021527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
34 Shih YF, Liu CJ. Hepatitis C Virus and Hepatitis B Virus Co-Infection. Viruses 2020;12:E741. [PMID: 32664198 DOI: 10.3390/v12070741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ, Yu ML. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Sci Rep 2018;8:15058. [PMID: 30305682 DOI: 10.1038/s41598-018-33448-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Lee S, Yoon H, Han J, Jang KL. Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection. J Gen Virol 2021;102. [PMID: 34882535 DOI: 10.1099/jgv.0.001701] [Reference Citation Analysis]
37 Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015;9:164. [PMID: 26215390 DOI: 10.1186/s13256-015-0630-8] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 10.9] [Reference Citation Analysis]
38 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Liu CJ, Tseng TC, Yang WT, Su TH, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. J Gastroenterol Hepatol 2019;34:410-7. [PMID: 30151861 DOI: 10.1111/jgh.14455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol 2017;23:4317-23. [PMID: 28706414 DOI: 10.3748/wjg.v23.i24.4317] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
41 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
42 Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
43 Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018;154:989-97. [PMID: 29174546 DOI: 10.1053/j.gastro.2017.11.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
44 Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, Colomba G, Craxì A, Di Marco V. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat 2018;25:72-9. [PMID: 28703895 DOI: 10.1111/jvh.12754] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
45 Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32:1754-1762. [PMID: 28230928 DOI: 10.1111/jgh.13771] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
46 Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, Liang PC, Tsai PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chung RT, Yu ML. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol 2020;73:62-71. [PMID: 32061869 DOI: 10.1016/j.jhep.2020.01.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
47 Wahle RC, Perez RM, Pereira PF, Oliveira EM, Emori CT, Uehara SN, Silva IS, Silva AE, Ferraz ML. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis 2015;19:533-7. [PMID: 25997784 DOI: 10.1016/j.bjid.2015.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
48 Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164. [PMID: 26215390 DOI: 10.1186/s13256-015-0630-810.1186/s13256-015-0630-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Liu CJ, Chen TC, Chen PJ, Wang HY, Tseng TC, Cheng HR, Liu CH, Chen DS, Kao JH. Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: comparison of genotypes B and C at various immune stages. J Gastroenterol Hepatol 2015;30:172-7. [PMID: 25040688 DOI: 10.1111/jgh.12654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Flisiak R. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther 2020;18:1045-54. [PMID: 32538232 DOI: 10.1080/14787210.2020.1782189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Liu CJ, Chu YT, Shau WY, Kuo RN, Chen PJ, Lai MS. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut. 2014;63:506-514. [PMID: 23676440 DOI: 10.1136/gutjnl-2012-304370] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
52 Hsi E, Huang CF, Dai CY, Juo SH, Chou WW, Huang JF, Yeh ML, Lin ZY, Chen SC, Wang LY. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. Antiviral Res. 2014;105:135-142. [PMID: 24637254 DOI: 10.1016/j.antiviral.2014.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
53 Hsieh MH, Yeh ML, Su TH, Liu TW, Huang CF, Huang CI, Wang SC, Huang JF, Dai CY, Kao JH, Chuang WL, Chen PJ, Liu CJ, Yu ML. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. J Formos Med Assoc 2018;117:497-504. [PMID: 28694000 DOI: 10.1016/j.jfma.2017.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
54 Yu ML, Yeh ML, Tsai PC, Huang CI, Huang JF, Huang CF, Hsieh MH, Liang PC, Lin YH, Hsieh MY, Lin WY, Hou NJ, Lin ZY, Chen SC, Dai CY, Chuang WL, Chang WY. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore) 2015;94:e690. [PMID: 25837762 DOI: 10.1097/MD.0000000000000690] [Cited by in Crossref: 65] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]